Boston Partners purchased a new position in shares of Mallinckrodt PLC (NYSE:MNK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 75,652 shares of the company’s stock, valued at approximately $3,390,000. Boston Partners owned 0.08% of Mallinckrodt PLC at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Capstone Asset Management Co. raised its position in Mallinckrodt PLC by 11.3% in the first quarter. Capstone Asset Management Co. now owns 28,318 shares of the company’s stock worth $1,262,000 after buying an additional 2,870 shares in the last quarter. Rice Hall James & Associates LLC raised its position in Mallinckrodt PLC by 2.9% in the first quarter. Rice Hall James & Associates LLC now owns 9,683 shares of the company’s stock worth $432,000 after buying an additional 277 shares in the last quarter. Retirement Systems of Alabama raised its position in Mallinckrodt PLC by 20.9% in the first quarter. Retirement Systems of Alabama now owns 139,082 shares of the company’s stock worth $6,199,000 after buying an additional 24,051 shares in the last quarter. Korea Investment CORP raised its position in Mallinckrodt PLC by 45.5% in the first quarter. Korea Investment CORP now owns 91,800 shares of the company’s stock worth $4,092,000 after buying an additional 28,700 shares in the last quarter. Finally, Profund Advisors LLC raised its position in Mallinckrodt PLC by 3.6% in the first quarter. Profund Advisors LLC now owns 6,399 shares of the company’s stock worth $285,000 after buying an additional 220 shares in the last quarter. 94.65% of the stock is currently owned by institutional investors.

Shares of Mallinckrodt PLC (MNK) opened at 36.13 on Tuesday. The firm’s market cap is $3.51 billion. Mallinckrodt PLC has a 1-year low of $35.04 and a 1-year high of $85.83. The firm’s 50-day moving average is $42.28 and its 200-day moving average is $45.03.

Mallinckrodt PLC (NYSE:MNK) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $1.85 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.12. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The firm had revenue of $824.50 million for the quarter, compared to analysts’ expectations of $829.56 million. During the same quarter last year, the business earned $2.03 EPS. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. On average, analysts anticipate that Mallinckrodt PLC will post $7.46 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://theolympiareport.com/2017/08/22/boston-partners-takes-position-in-mallinckrodt-plc-mnk.html.

A number of equities analysts recently issued reports on MNK shares. Zacks Investment Research lowered shares of Mallinckrodt PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 target price on shares of Mallinckrodt PLC in a research report on Thursday, August 3rd. Canaccord Genuity set a $87.00 target price on shares of Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Monday, July 17th. UBS AG set a $70.00 target price on shares of Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Deutsche Bank AG set a $68.00 target price on shares of Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Wednesday, May 31st. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $71.25.

In related news, VP Hugh M. O’neill purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were bought at an average price of $40.24 per share, for a total transaction of $40,240.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Coleman N. Lannum III purchased 1,350 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was bought at an average price of $42.89 per share, for a total transaction of $57,901.50. Following the transaction, the vice president now directly owns 30,955 shares of the company’s stock, valued at approximately $1,327,659.95. The disclosure for this purchase can be found here. Insiders purchased 3,850 shares of company stock worth $157,687 in the last 90 days. 0.53% of the stock is owned by company insiders.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).

Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.